News|Articles|June 27, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016
  • Volume 11
  • Issue 7

Catalent Launches FastChain Service for Clinical Supply Management

Catalent’s FastChain service is a continuous GMP approach to clinical supply management that decouples primary packaging from secondary packaging, and enables the final assembly, labeling, and distribution of clinical supplies on a regional basis.

CDMO Catalent Pharma Solutions announced on June 27, 2016 the launch of its FastChain service, which the company says enables greater speed, flexibility, and efficiency in the management of global clinical supplies.

According to Catalent, this FastChain service is a continuous GMP approach to clinical supply management that decouples primary packaging from secondary packaging, and enables the final assembly, labeling, and distribution of clinical supplies on a regional basis.

This demand-led supply model reduces the need to pre-package bulk supplies far in advance of the study start, creates the ability to pool supplies across protocols, and has the potential to reduce clinical waste from upwards of 200% or more to less than 20%.

Investigator sites will receive only the clinical supplies they need to meet actual patient demand within a matter of days rather than weeks. Furthermore, mid-study changes such as revised dosing schedules or the addition of countries and clinical sites will be easy to accommodate for FastChain customers.

Catalents says it is making significant investments in its facilities worldwide to include specialized packaging lanes, and integrated systems and processes to support demand-led studies. The FastChain service will be made available for both ambient and cold chain studies on a global basis.

Source: Catalent


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.